Nature Communications (May 2017)

Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity

  • Joseph S. Bednash,
  • Nathaniel Weathington,
  • James Londino,
  • Mauricio Rojas,
  • Dexter L. Gulick,
  • Robert Fort,
  • SeungHye Han,
  • Alison C. McKelvey,
  • Bill B. Chen,
  • Rama K. Mallampalli

DOI
https://doi.org/10.1038/ncomms15203
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 13

Abstract

Read online

How NALP7 inflammasome formation is regulated is unclear. Here the authors show that STAMBP prevents lysosomal degradation of NALP7 and present BC-1471 as a potential therapeutic STAMBP inhibitor, showing it can reduce TLR-induced IL-1β production.